Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis : a randomized, placebo-controlled, six-month, phase 2 study
© The Author(s) [2024]. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research..
Anabolic treatment is indicated for high and very-high risk patients with osteoporosis, but acceptance is limited because current anabolic medications require subcutaneous injections. The purpose of this study was to assess the effects of a novel orally administered parathyroid hormone (PTH) tablet on serum markers of bone formation [N-terminal propeptide of Type I procollagen (PINP) and osteocalcin (OC)] and bone resorption [crosslinked C-telopeptide (CTX)], bone mineral density (BMD) and safety in postmenopausal women with low BMD or osteoporosis. In this 6-month, double-blind, placebo-controlled study, 161 patients were randomized to oral PTH tablets containing 0.5, 1.0, 1.5, or 2.5 mg or placebo daily. Biochemical markers were assessed at 1, 2, 3 and 6 months and BMD of lumbar spine, total hip and femoral neck was measured at 6 months. Biochemical marker changes were dose dependent with minimal or no effect at the two lowest doses. At the highest dose (2.5 mg once daily), serum PINP and OC levels increased 30% within 1 month after oral PTH initiation (p < 0.0001), remained elevated through 3 months and were back to baseline at 6 months. In contrast, serum CTX levels declined 16% and 21% below baseline at 3 and 6 months respectively (both p ≤ 0.02). At 6 months, 2.5 mg tablets increased mean BMD vs placebo of the lumbar spine by 2.7%, total hip by 1.8%, and femoral neck by 2.8% (all p ≤ 0.01). There were no drug-related serious adverse events. The most common adverse events were headache, nausea, and dizziness. In contrast to subcutaneous PTH, the oral PTH tablet appears to increase BMD rapidly by the dual mechanism of stimulating formation and inhibiting bone resorption. This might be the first effective oral anabolic alternative to subcutaneous administration for the treatment of low BMD or osteoporosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - (2024) vom: 05. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tripto-Shkolnik, Liana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EBP05/EB613 |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/jbmr/zjae057 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370683889 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370683889 | ||
| 003 | DE-627 | ||
| 005 | 20240406232718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jbmr/zjae057 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM370683889 | ||
| 035 | |a (NLM)38578978 | ||
| 035 | |a (PII)zjae057 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tripto-Shkolnik, Liana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis |b a randomized, placebo-controlled, six-month, phase 2 study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) [2024]. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. | ||
| 520 | |a Anabolic treatment is indicated for high and very-high risk patients with osteoporosis, but acceptance is limited because current anabolic medications require subcutaneous injections. The purpose of this study was to assess the effects of a novel orally administered parathyroid hormone (PTH) tablet on serum markers of bone formation [N-terminal propeptide of Type I procollagen (PINP) and osteocalcin (OC)] and bone resorption [crosslinked C-telopeptide (CTX)], bone mineral density (BMD) and safety in postmenopausal women with low BMD or osteoporosis. In this 6-month, double-blind, placebo-controlled study, 161 patients were randomized to oral PTH tablets containing 0.5, 1.0, 1.5, or 2.5 mg or placebo daily. Biochemical markers were assessed at 1, 2, 3 and 6 months and BMD of lumbar spine, total hip and femoral neck was measured at 6 months. Biochemical marker changes were dose dependent with minimal or no effect at the two lowest doses. At the highest dose (2.5 mg once daily), serum PINP and OC levels increased 30% within 1 month after oral PTH initiation (p < 0.0001), remained elevated through 3 months and were back to baseline at 6 months. In contrast, serum CTX levels declined 16% and 21% below baseline at 3 and 6 months respectively (both p ≤ 0.02). At 6 months, 2.5 mg tablets increased mean BMD vs placebo of the lumbar spine by 2.7%, total hip by 1.8%, and femoral neck by 2.8% (all p ≤ 0.01). There were no drug-related serious adverse events. The most common adverse events were headache, nausea, and dizziness. In contrast to subcutaneous PTH, the oral PTH tablet appears to increase BMD rapidly by the dual mechanism of stimulating formation and inhibiting bone resorption. This might be the first effective oral anabolic alternative to subcutaneous administration for the treatment of low BMD or osteoporosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EBP05/EB613 | |
| 650 | 4 | |a Entera Bio | |
| 650 | 4 | |a oral PTH | |
| 650 | 4 | |a oral hPTH(1-34) | |
| 650 | 4 | |a oral teriparatide | |
| 650 | 4 | |a osteoanabolics | |
| 650 | 4 | |a osteoporosis treatment | |
| 700 | 1 | |a Szalat, Auryan |e verfasserin |4 aut | |
| 700 | 1 | |a Tsvetov, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Rouach, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Sternberg, Chana |e verfasserin |4 aut | |
| 700 | 1 | |a Hoppe, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a Burshtein, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Galitzer, Hillel |e verfasserin |4 aut | |
| 700 | 1 | |a Toledano, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Harari, Gil |e verfasserin |4 aut | |
| 700 | 1 | |a Santora, Arthur C |e verfasserin |4 aut | |
| 700 | 1 | |a Cosman, Felicia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research |d 1991 |g (2024) vom: 05. Apr. |w (DE-627)NLM012611115 |x 1523-4681 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jbmr/zjae057 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 | ||